@article{MTMT:35061032,
	title = {The Evaluation of Lipid-Lowering Treatment in Patients with Acute Coronary Syndrome in a Hungarian Invasive Centre in 2015, 2017, and during the COVID-19 Pandemic—The Comparison of the Achieved LDL-Cholesterol Values Calculated with Friedewald and Martin–Hopkins Methods},
	url = {https://m2.mtmt.hu/api/publication/35061032},
	author = {Márk, László and Fülöp, Péter and Lőrincz, Hajnalka and Dani, Győző and Tajtiné, Krisztina Fazekas and Thury, Attila and Paragh, György},
	doi = {10.3390/jcm13123398},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {13},
	unique-id = {35061032},
	abstract = {Background/Objectives: Patients with acute coronary syndrome (ACS) represent a vulnerable population. We aimed to investigate serum lipid levels of patients with ACS upon admission and during one year of the COVID-19 pandemic in a rural county hospital, and compared these findings with the data of patients with ACS in 2015 and 2017. The secondary aim of this paper was the comparison of the LDL-C values calculated with the Friedewald and Martin–Hopkins methods. Methods: A retrospective analysis of lipid-lowering data of patients treated with ACS in 2015, 2017 and in a COVID-19 year (1 April 2020–31 March 2021) was performed; the patient’s numbers were 454, 513 and 531, respectively. Results: In the COVID-19 period one year after the index event, only 42% of the patients had lipid values available, while these ratios were 54% and 73% in 2017 and in 2015, respectively. Using the Friedewald formula, in the COVID-19 era the median of LDL cholesterol (LDL-F) was 1.64 (1.09–2.30) mmol/L at six months and 1.60 (1.19–2.27) mmol/L at one year, respectively. These values were 1.92 (1.33–2.27) mmol/L and 1.73 (1.36–2.43) mmol/L using the Martin–Hopkins method (LDL-MH). The LDL-F yielded significantly lower values (15% lower at six months, p = 0.044; and 8% lower at one year, p = 0.014). The LDL-F reached the previous target of 1.8 mmol/L during the COVID-19 pandemic 36% at one year vs. 48% in 2017, and 37% in 2015. The recent target LDL-C level of 1.4 mmol/L was achieved in 22% of cases in the COVID-19 pandemic, 16% in 2015 and 19% in 2017. Conclusions: A significantly lower proportion of patients with ACS had available lipid tests during the COVID-19 pandemic. Besides the lower number of available samples, the proportion of achieved 1.4 mmol/L LDL-C target lipids was stable. More rigorous outpatient care in the follow-up period may help to improve the quality of lipid lowering treatments and subsequent secondary cardiovascular prevention. If direct LDL-C determination is not available, we prefer the LDL calculation with the Martin–Hopkins method.},
	year = {2024},
	eissn = {2077-0383},
	pages = {3398}
}

@article{MTMT:34070083,
	title = {Influencing Mechanism of Large-dose of Atorvastatin in Serum Visfatin, MMP-9, and Blood Fat Levels of Patients with Acute Coronary Syndromes},
	url = {https://m2.mtmt.hu/api/publication/34070083},
	author = {Ma, W. and Liu, W. and Mu, J.},
	doi = {10.14715/cmb/2023.69.3.16},
	journal-iso = {CELL MOL BIOL},
	journal = {CELLULAR AND MOLECULAR BIOLOGY},
	volume = {69},
	unique-id = {34070083},
	issn = {0145-5680},
	year = {2023},
	eissn = {1165-158X},
	pages = {118-123}
}

@article{MTMT:31710478,
	title = {Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients},
	url = {https://m2.mtmt.hu/api/publication/31710478},
	author = {Zhu, Ling and Cui, Qianwei and Liu, Ying and Liu, Zhongwei and Zhang, Yong and Liu, Fuqiang and Wang, Junkui},
	doi = {10.12659/MSM.925114},
	journal-iso = {MED SCI MONIT},
	journal = {MEDICAL SCIENCE MONITOR},
	volume = {26},
	unique-id = {31710478},
	issn = {1234-1010},
	year = {2020},
	eissn = {1643-3750}
}